Harmony Biosciences’ (HRMY) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Harmony Biosciences (NASDAQ:HRMY) in a report published on Thursday,Benzinga reports. The firm currently has a $55.00 price target on the stock. HC Wainwright also issued estimates for Harmony Biosciences’ Q4 2026 earnings at $0.73 EPS, FY2026 earnings at $3.37 EPS, Q2 2027 earnings at $1.02 EPS, Q3 2027 earnings at $1.21 EPS, Q4 2027 earnings at $1.46 EPS, FY2027 earnings at $4.50 EPS, FY2028 earnings at $6.06 EPS, FY2029 earnings at $5.90 EPS and FY2030 earnings at $7.30 EPS.

Other equities analysts have also recently issued reports about the stock. Mizuho set a $49.00 target price on shares of Harmony Biosciences in a research note on Thursday, October 29th. UBS Group restated a “neutral” rating and set a $37.00 price objective on shares of Harmony Biosciences in a report on Wednesday, August 5th. Weiss Ratings lowered shares of Harmony Biosciences from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, November 9th. Wolfe Research initiated coverage on shares of Harmony Biosciences in a research note on Wednesday, August 26th. They issued an “outperform” rating and a $60.00 target price for the company. Finally, Oppenheimer reissued an “outperform” rating on shares of Harmony Biosciences in a research report on Thursday, September 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Harmony Biosciences has an average rating of “Moderate Buy” and a consensus price target of $48.00.

Harmony Biosciences Stock Performance

Shares of HRMY stock traded down $0.04 during trading on Thursday, reaching $33.76. The company had a trading volume of 844,891 shares, compared to its average volume of 1,221,212. The firm’s 50 day simple moving average is $38.65 and its two-hundred day simple moving average is $34.62. Harmony Biosciences has a one year low of $25.90 and a one year high of $43.49. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.44 and a quick ratio of 3.42. The company has a market capitalization of $1.98 billion, a PE ratio of 11.18, a PEG ratio of 0.36 and a beta of 1.00.

Harmony Biosciences (NASDAQ:HRMY) last announced its earnings results on Wednesday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.28). Harmony Biosciences had a return on equity of 18.55% and a net margin of 18.05%. The company had revenue of $268.92 million for the quarter, compared to the consensus estimate of $272.05 million. During the same period in the previous year, the company earned $1.08 EPS. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. Sell-side analysts forecast that Harmony Biosciences will post 3.55 earnings per share for the current year.

Insider Transactions at Harmony Biosciences

In other Harmony Biosciences news, insider Kumar Budur sold 35,852 shares of the stock in a transaction on Friday, September 18th. The stock was sold at an average price of $43.05, for a total value of $1,543,428.60. Following the transaction, the insider directly owned 13,115 shares in the company, valued at approximately $564,600.75. This trade represents a 73.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders have sold 72,406 shares of company stock worth $3,108,520. 11.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Empowered Funds LLC boosted its position in shares of Harmony Biosciences by 9.8% during the third quarter. Empowered Funds LLC now owns 125,793 shares of the company’s stock worth $4,939,000 after purchasing an additional 11,255 shares in the last quarter. Caxton Associates LLP acquired a new position in shares of Harmony Biosciences in the third quarter valued at approximately $907,000. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Harmony Biosciences during the 3rd quarter worth about $4,892,000. Polymer Capital Management US LLC bought a new position in shares of Harmony Biosciences during the third quarter worth about $256,000. Finally, Advisors Asset Management Inc. bought a new stake in shares of Harmony Biosciences in the third quarter worth $102,000. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences News Roundup

Investors following HRMY have been watching these news items:

• Positive Sentiment: HC Wainwright raised its 2028–2030 EPS forecasts, including 2028 to $6.06 from $5.81 and 2030 to $7.30 from $7.11, while retaining its “Buy” rating and $55 target. Article: Harmony Biosciences Stock Keeps Buy Rating at HC Wainwright
• Negative Sentiment: The analyst lowered estimates for several nearer-term periods: FY2026 EPS to $3.37 from $3.52, FY2027 to $4.50 from $4.69, and quarterly forecasts for Q4 2026 through Q4 2027. This broad downward revision signals a more cautious earnings outlook. Harmony Biosciences analyst information
• Negative Sentiment: Recent quarterly results also showed profit falling despite 12% sales growth; EPS and revenue came in below consensus, adding pressure to the near-term earnings picture. Article: Harmony Biosciences Profit Falls Despite 12% Sales Growth

Harmony Biosciences Company Profile

Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for people living with rare neurological diseases. The company’s work centers on therapies intended to address significant unmet medical needs. Its lead product, WAKIX (pitolisant), is approved in the United States to treat excessive daytime sleepiness or cataplexy in adults and pediatric patients aged 6 years and older with narcolepsy. Harmony launched WAKIX in the United States in 2019. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony primarily serves the U.S. market.